IOL Chemicals and Pharmaceuticals has commenced the commercial production of paracetamol with an installed capacity of 1800 MTPA along with backward integration of Para Amino Phenol (PAP) with effect from 22nd April 2022.

The company is manufacturing paracetamol in its existing Unit No 4, which has been converted as a multiproduct facility, with a cost of about Rs 100 Lakh whereas PAP is being manufactured in a part of Unit No 9. The company will continue to use Unit 4 & Unit 9 for manufacturing other products as per market conditions, the company said in a statement.

Further, considering the present market scenario, the company is in the process of enhancing the installed capacity for manufacturing the paracetamol from 1800 MTPA to 3600 MTPA with a capex of about Rs 25 crore, which is expected to be completed during the 3rd quarter of FY 2023. All the capex is being met through internal accruals only.

Paracetamol, also known as Acetaminophen, is an Active Pharma ingredient (API) that is used to treat fever and mild pain, whereas PAP is used as an intermediate to manufacture paracetamol.